NeuroPace (NPCE) said late Monday that it expects "minimal impact" to its operations and financial results from the Trump administration's tariffs .
The medical device company said it manufactures and sells the "vast majority" of its devices in the US and has "limited" supply chain activities outside the country for its responsive neurostimulation System.
The firm expects "no material" impact on gross margin for DIXI Medical SEEG products.
It expects "minimal impact" to gross margin for fiscal 2025 and is reiterating its gross margin guidance for 2025.
NeuroPace will report Q1 financial results after market close on May 13.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。